Spyre Therapeutics (SYRE) Assets (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Assets data on file, last reported at $764.0 million in Q1 2026.

• Quarterly Assets rose 34.08% year-over-year to $764.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.0 million (up 34.08% YoY) and the FY2025 annual result came in at $777.8 million, up 27.82% from the prior year.
• Assets declined to $764.0 million in Q1 2026, from $777.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $777.8 million in Q4 2025 to a low of $52.5 million in Q1 2023.
• A 5-year average of $370.9 million and a median of $421.1 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets plunged 49.17% — and 2024, when it surged 829.6%.
• Tracing SYRE's Assets over 5 years: stood at $71.1 million in 2022, then surged by 380.52% to $341.9 million in 2023, then surged by 77.99% to $608.5 million in 2024, then advanced by 27.82% to $777.8 million in 2025, then retreated by 1.78% to $764.0 million in 2026.
• The last three Assets figures came in at $764.0 million (Q1 2026), $777.8 million (Q4 2025), and $504.6 million (Q3 2025), per Business Quant data.